Middle East and Africa Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others) Industry Trends and Forecast to 2029.
Market Definition and Insights
Syndromic multiplex diagnostic is a type of advanced diagnostic test utilised to detect infectious diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. The syndromic multiplex diagnostic also helps the clinicians or hospitals to detect the symptoms and signs of the various types of diseases. This lets the health care providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly.
Syndromic multiplex testing is used to diagnose many pathogens simultaneously. In the syndromic multiplex diagnostic, various types of reagents & consumables and instruments & accessories are used, which helps maintain accuracy and provide fast diagnosis results. These multiplex tests are rapidly diagnosed with certain infections, allowing clinical management decisions to be made promptly. The tests based on multiplex technology are known as test panels. The panels used in syndromic testing are designed to diagnose multiple diseases associated with the same or similar syndrome type. These panels help evaluate the cause of the disease at the point of care. Gastrointestinal panels and respiratory panels are the types of syndromic panels.
Syndromic multiplex testing utilizes the advanced technology of multiplex PCR which provides accurate and fast diagnostic results, with the help of the multiple panels used in syndromic multiplex diagnostic to provide diagnostic results within an hour. The new generations of syndromic multiplex can rapidly identify the common type of pathogens in the respiratory specimens, blood and cerebrospinal. The use of multiplex panels is associated with quicker turnaround time, reduction of other unnecessary laboratory tests, faster diagnosis and targeted treatment.
Data Bridge Market Research analyses that the Middle East and Africa syndromic multiplex diagnostic market will grow at a CAGR of 6.4% during the forecast period of 2022 to 2029.
2022 to 2029
Revenue in USD Million, Volumes in Units, Pricing in USD
Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection Type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, Sexually Transmitted Disease Panel, Blood-Sepsis Panel, Meningitis Panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others),
South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa
Market Players Covered
BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc. (South Korea), Luminex Corporation. A DiaSorin Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cepheid (A subsidiary of Danaher (U.S.)), QIAGEN (Germany), Abbott (U.S.), Hologic, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Siemens Healthcare GmbH (Germany), Biocartis (Belgium), QuantuMDx Group Ltd. (U.K.), Prominex Inc. (U.S.), Curetis (A subsidiary of OpGen, Inc.) (Germany)
Syndromic Multiplex Diagnostic Market Dynamics
- Rise in prevalence of infectious diseases
The rising incidence of infectious bacterial and viral diseases impacts the market's demand because, in the syndromic testing, multiplex real-time PCR technique and the syndromic approach are used for molecular diagnostics of infectious diseases.
- Increasing awareness towards early diagnosis
People are getting more aware of the early diagnosis of diseases required for effective treatment. The multiplex diagnosis provides fast and accurate results; hence, the increase in demand for these instruments is driving the market's growth.
- Development of Diagnostic Laboratories
Diagnostic laboratories play a central role in healthcare by providing accurate information, the foundation for effective care. The requirement of reliable, fast, and accurate test results is vital in emergency rooms, critical care centers, and other situations where treatment decisions must be based on the diagnostic results. Hence, the development of diagnostic laboratories is acting as opportunity for market growth.
- Rising Diagnostic Healthcare Expenditure
The growing healthcare expenditure is expected to increase the availability of services and affordability for the population to opt for better and more precise diagnostic services to manage their diseases. The increase in healthcare expenditure ensures better availability of diagnostic services. Hence, huge health care expenditure is a favourable factor and is acting as an opportunity for the growth of the syndromic multiplex diagnostic market.
- Explicit Limitation of Syndromic Multiplex Testing
The current limitations of syndromic multiplex diagnostic are that the molecular assays used in this application can identify a limited or few numbers of microbial targets, also the assays have moderate sensitivity, which may hamper the market growth.
Post COVID-19 Impact on Syndromic Multiplex Diagnostic market
COVID-19 has positively affected the market. Market players are launching different products for the detection of the SARS-CoV virus. There is an increase in approval of products by regulatory bodies after post COVID-19, which leads to an increase in market growth.
- In December 2021, BD expanded its BD COR system to include a new MX instrument for molecular testing of infectious diseases. The MX instrument expands the platform and automates essential testing assays for women's health and STI testing using a multiplex PCR assay design. This has helped the company to increase its portfolio.
Syndromic Multiplex Diagnostic Market Scope
The syndromic multiplex diagnostic market is categorized into five segments: product and services, infection type, disease, panels type, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product and Services
- Reagents & Consumables
- Instruments, Software & Accessories
Based on products and services, the Middle East and Africa syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services.
Based on infection type, the Middle East and Africa syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal
- Respiratory Infection
- Sexually Transmitted Infections
Based on disease, the Middle East and Africa syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others
- Respiratory Panel
- GI-Enteric Panel
- Sexually Transmitted Disease Panel
- Blood-Sepsis Panel
- Meningitis Panel
Based on panels type, the Middle East and Africa syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others
- Clinical Laboratories
- Pharmaceutical & Biotechnology Companies
- Research Institutes
Based on end user, the Middle East and Africa syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical & biotechnology companies, research institutes and others
Syndromic Multiplex Diagnostic Market Regional Analysis/Insights
The syndromic multiplex diagnostic market is analysed and market size insights and trends are provided by country, product and services, infection type, disease, panels type and end user as referenced above.
The countries covered in the report are South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa.
South Africa syndromic multiplex diagnostic market is expected to grow due to an increase in the prevalence of infectious diseases.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands impact on sales channels are considered while providing forecast analysis of the country data.
Syndromic Multiplex Diagnostic Market Share Analysis
The syndromic multiplex diagnostic market competitive landscape provides details of a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Saudi Arabia presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the syndromic multiplex diagnostic market.
Some of the major players operating in the Middle East and Africa syndromic multiplex diagnostic market are BioFire Diagnostics (A Subsidiary of bioMérieux SA), Seegene Inc., Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (A subsidiary of Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Biocartis, QuantuMDx Group Ltd., Prominex Inc., Curetis (A subsidiary of OpGen, Inc.), among others.